Subclinical sensitization with diphenylcyclopropenone is sufficient for the treatment of alopecia areata: Retrospective analysis of 159 cases - 28/02/18
Abstract |
Background |
Contact immunotherapy with diphenylcyclopropenone (DPCP) is presently considered the treatment of choice for extensive alopecia areata. However, a major concern with contact immunotherapy is that it causes various adverse effects (AEs) that contribute to discontinuation of treatment.
Objective |
We investigated whether a modified DPCP treatment protocol can promote hair regrowth with fewer AEs.
Methods |
All patients were sensitized with 0.1% DPCP and began treatment with 0.01% DPCP. Thereafter, the DPCP concentration was slowly increased according to the treatment response and AEs. This was a retrospective review of DPCP treatment with modified protocols in 159 patients with alopecia areata.
Results |
Of the 159 patients, 46 (28.9%) showed a complete response and 59 (37.1%) showed a partial response. No patients had AEs after sensitization. During the treatment, only 3 patients (1.9%) showed severe AEs, and 55 showed moderate AEs; however, all were well controlled with antihistamines alone or antihistamines and medium-potency topical steroids. There was no association between treatment response and AEs.
Limitations |
Sample size, subject composition, and the retrospective study design represent potential limitations.
Conclusion |
A modified DPCP treatment protocol with subclinical sensitization could induce a favorable therapeutic response and result in fewer AEs.
Le texte complet de cet article est disponible en PDF.Key words : adverse effect, alopecia areata, diphenylcyclopropenone, DPCP, immunotherapy, sensitization
Abbreviations used : AA, AE, CR, DPCP, SADBE
Plan
Funding sources: None. |
|
Conflicts of interest: None disclosed. |
|
Reprints not available from the authors. |
Vol 78 - N° 3
P. 515 - mars 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?